All you need to know about enfortumab vedotin (EV) & pembro in bladder cancer in 25 minutes! We are joined in studio by bladder cancer gurus Shilpa Gupta (Cleveland Clinic, USA) and Andrew Weickhardt (Austin Health, AUS) to get an update on the role of EV-pembro in both muscle-invasive localised bladder cancer, and metastatic bladder cancer. Shilpa led a very nice paper in this month's European Urology titled optimal management of muscle, invasive bladder, cancer, so we were very keen to pick her brains on this, especially the emerging role of peri-operative EV-pembro. We also picked herself and Andrew‘s brains for the optimal management of metastatic bladder cancer, as they were both involved in the historic EV 302 trial which has transformed the management of metastatic bladder cancer. Must know stuff! A great overview of where we stand today. Thanks so much to Shilpa for dropping into Gu Cast while on holidays in Australia! 

With your usual hosts are Declan Murphy and Reno Eapn

This is a Themed Podcast, supported by our Platinum Partners, Astellas

Disclaimer:

Enfortumab vedotin in combination with pembrolizumab is not registered for MIBC in Australia and a number of other countries. Please refer to the registration status in your country before prescribing

Links:

Eur Urol paper on optimal management of MIBC